Red Light Holland Completes Acquisition of Filament Health to Bolster Botanical Drug Platform

Key Facts

Red Light Holland has officially completed the acquisition of all issued and outstanding common shares of Filament Health through a statutory plan of arrangement, following final approval from the Supreme Court of British Columbia. The transaction became effective on April 29, 2026, establishing a comprehensive integrated platform that bridges botanical drug development with global consumer distribution. This merger adds a significant intellectual property portfolio to Red Light Holland, including over 70 patents and proprietary extraction technologies previously held by Filament. The successful closing marks a strategic milestone in the medical psilocybin sector, resolving all previous regulatory and legal requirements. The combined entity is now positioned to leverage these assets to accelerate market expansion and pharmaceutical innovation on a global scale.

Version History